Update on the use of magnesium sulphate for fetal neuroprotection in preterm birth.
Arch Argent Pediatr
; 113(4): 345-51, 2015 08.
Article
em En, Es
| MEDLINE
| ID: mdl-26172011
The administration of magnesium sulphate to mothers at risk for preterm birth for fetal neuroprotection has demonstrated to reduce the risk of cerebral palsy and gross motor dysfunction by 30-40%. Although there is controversy regarding the regimen of administration of magnesium sulphate, the gestational age limit, the extent of its potential benefit or even if it provides any benefit, current evidence is enough to support the use of magnesium sulphate in women at imminent risk for preterm delivery before 32 weeks of gestation. The objective of this study is to describe available evidence and current recommendations regarding neuroprotection with magnesium sulphate.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Encefalopatias
/
Doenças Fetais
/
Doenças do Prematuro
/
Sulfato de Magnésio
Tipo de estudo:
Guideline
Limite:
Humans
/
Newborn
Idioma:
En
/
Es
Revista:
Arch Argent Pediatr
Ano de publicação:
2015
Tipo de documento:
Article
País de publicação:
Argentina